欧林生物终止向特定对象发行股票事项

Core Viewpoint - The company has decided to terminate the issuance of shares to specific targets through a simplified procedure due to current market conditions and its own development plans [1] Group 1 - The company's board, management, and intermediaries have been actively working on the share issuance since the initial announcement [1] - The decision to terminate the share issuance will not adversely affect the company's normal production and operations [1] - The "Vaccine R&D Production Base Technical Transformation Project" is progressing as planned [1]